Loading...
XTAE
NXTG
Market cap22mUSD
Apr 29, Last price  
104.50ILS
1D
0.00%
1Q
41.79%
Jan 2017
-94.89%
Name

Nextage Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
9,381.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
87.20%
Rev. gr., 5y
17.99%
Revenues
876k
28,000405,000383,000297,000191,00091,0000876,000
Net income
-4m
L-35.19%
-8,746,000-5,732,000-8,735,000-2,088,000-15,966,000-7,728,000-5,985,000-3,879,000
CFO
-2m
L-62.38%
-6,998,000-5,671,000-4,952,000-5,005,000-7,186,000-2,409,000-6,012,000-2,262,000
Dividend
Jun 09, 200368000 ILS/sh

Profile

Nextage Therapeutics Ltd develops cannabinoid-based products. The company is based in Ness Ziona, Israel.
URL
https://m-medic.com/
IPO date
Jan 01, 1993
Employees
42
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
876
 
Cost of revenue
3,040
3,806
Unusual Expense (Income)
NOPBT
(2,164)
(3,806)
NOPBT Margin
Operating Taxes
(115)
Tax Rate
NOPAT
(2,164)
(3,691)
Net income
(3,879)
-35.19%
(5,985)
-22.55%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,162
3,443
BB yield
-11.89%
Debt
Debt current
308
211
Long-term debt
216
123
Deferred revenue
Other long-term liabilities
36
43
Net debt
120
(717)
Cash flow
Cash from operating activities
(2,262)
(6,012)
CAPEX
(4)
Cash from investing activities
3
17
Cash from financing activities
1,478
3,392
FCF
(262)
(3,154)
Balance
Cash
404
1,051
Long term investments
Excess cash
360
1,051
Stockholders' equity
21,443
(426)
Invested Capital
(2,683)
377
ROIC
187.67%
ROCE
93.16%
7,767.35%
EV
Common stock shares outstanding
29,181
Price
0.34
-42.44%
0.58
-73.65%
Market cap
9,776
 
EV
10,059
EBITDA
(2,036)
(3,749)
EV/EBITDA
Interest
50
25
Interest/NOPBT